Last updated: February 13, 2026
What Is the Current Market Status for Drug NDC 00054-3120?
The drug identified by NDC 00054-3120 is Xyrem (sodium oxybate), marketed primarily for severe narcolepsy with cataplexy. It is marketed by Jazz Pharmaceuticals, with approved indications in the US, EU, and other markets.
Market approval and usage:
- Approved in the United States since 2002.
- Also approved in the EU, Canada, and several other countries.
- Primarily prescribed for narcolepsy with cataplexy; usage has expanded to off-label indications such as alcohol dependence and fibromyalgia.
Market share and sales:
- In 2022, Jazz Pharmaceuticals reported global sales of Xyrem at approximately $964 million [1].
- US sales account for the majority, around 85%, reflecting its primary market presence.
- Growth driven by increased diagnosis rates and expanded indication approval.
Patent and exclusivity status:
- Xyrem's initial patents expired in 2014.
- Extended exclusivity through formulation patents and secondary patents, some of which have faced legal challenges.
- Licensing agreements and potential biosimilar entries could impact future market dynamics.
How Is the Market for Xyrem Positioned in the Broader Neurological Disorder Sector?
- The narcolepsy treatment market is projected to grow at a compound annual growth rate (CAGR) of around 8% through 2027, driven by increased disease awareness and diagnosis.
- Alternative treatments include modafinil (Provigil), armodafinil (Nuvigil), and off-label use of stimulants.
- Limited competition exists due to unique mechanism (GABA receptor activity) and regulatory barriers.
- Biosimilar and generic development activities are ongoing, but no approved biosimilar for sodium oxybate exists as of 2023.
What Are the Price Trends and Projections for NDC 00054-3120?
Current Pricing
Price Trends (2018-2023)
- Prices have remained relatively stable in recent years.
- Noticeable pricing pressure started around 2015 when generic formulations entered markets in some countries.
- US market has seen discounts via patient assistance programs but no significant reduction in list prices.
Future Price Projections
-
Market exclusivity expiry considerations:
- Patent expirations related to Xyrem occurred around 2014, but secondary patents delayed generic entry.
-
Potential biosimilar or generic entries:
- Pending patent challenges and biosimilar development could introduce price competition within 2-4 years.
- Conservative estimate suggests a 20-30% price reduction in the US if biosimilars or generics are approved and marketed.
-
Regulatory and reimbursement factors:
- Payers are likely to negotiate discounts, influencing actual transaction prices.
- A shift towards biosimilars could reduce prices further, with projected declines up to 50% over the next 5 years if biosimilars enter at scale.
Pricing Impact of Market Dynamics
| Scenario |
Impact on Price |
Timeline |
| Continued patent protections |
Stable current prices |
Next 1-2 years |
| Patent challenges succeed; biosimilars enter |
Price reductions up to 30% |
2-4 years |
| Wider biosimilar adoption |
Price declines up to 50% |
5+ years |
What Are the Key Regulatory and Competitive Factors Influencing Future Market and Prices?
- Regulatory approval pathways for biosimilars under the Biologics Price Competition and Innovation Act (BPCIA) facilitate biosimilar development but require demonstration of biosimilarity and interchangeability.
- Legal challenges to patents could open the door for generics earlier than projected.
- Market entry barriers include complex manufacturing, high development costs, and limited clinical data for biosimilars.
- Reimbursement policies heavily influence price realizations, especially regarding approval and substitution rules.
What Are the Risks and Opportunities for Stakeholders?
Risks:
- Early patent expiration and legal actions threaten current exclusivity.
- Slow biosimilar approval cycles could delay price reductions.
- Off-label uses may introduce regulatory scrutiny or restrictions affecting prescribing patterns.
Opportunities:
- Expansion into new indications could sustain sales growth.
- Strategic delay or contest of biosimilar entries prolongs exclusivity.
- Price discounts via negotiated rebates may improve market penetration without immediate list price reductions.
Key Takeaways
- Market position: Xyrem has dominant market share in narcolepsy treatment, with near-monopoly status aided by patent protections and regulatory exclusivity.
- Sales performance: Global sales approached $1 billion in 2022, with US markets accounting for over 85%.
- Pricing outlook: Prices are stable in the short term; potential biosimilar or generic competition could reduce prices by 20-50% within 2-5 years.
- Regulatory landscape: Patent litigations and biosimilar development activities heavily influence future market dynamics.
- Market risks: Patent challenges, biosimilar approvals, and reimbursement negotiations could significantly impact prices and revenues.
FAQs
Q1: When will biosimilars for sodium oxybate likely enter the market?
A: If patent challenges succeed and biosimilar pathways are pursued actively, entries could occur within 2-4 years, possibly as early as 2025.
Q2: How does patent expiration impact the price of Xyrem?
A: While original patents expired in 2014, secondary patents have delayed generic entry. Their expiration or invalidation could lead to price reductions.
Q3: Are there existing biosimilars for sodium oxybate?
A: No biosimilars are approved for sodium oxybate as of 2023. Development activities are ongoing but face scientific and regulatory hurdles.
Q4: What factors most influence the future pricing of Xyrem?
A: Patent litigations, biosimilar approval and market entry, reimbursement policies, and competitive dynamics are the key factors.
Q5: What strategies could Jazz Pharmaceuticals use to defend Xyrem’s market position?
A: Patent protections, expanding approved indications, and establishing strong reimbursement agreements are primary strategies to sustain sales and pricing.
Citations:
[1] Jazz Pharmaceuticals. 2022 Annual Report.
